SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

DRREDDYS LABORATORIES

BSE: 500124 19 Aug 2025
Healthcare
₹ 1246.4
Dr. Reddy's Laboratories Ltd., specializes in Pharmaceuticals within the Healthcare sector.

DRREDDYS LABORATORIES - Share Price & Details

Market Cap
₹1,03,744
High /Low
1,421 / 1,020
Stock P/E
18.3
Book Value
₹402.0
Dividend Yield
0.64
ROCE
22.7
ROE
₹18.0
Face Value
1.0
PEG Ratio
0.48
EVEBITDA
₹10.8
Debt
4,677
CMP / FCF
43.0
Debt to equity
₹0.14
NP Ann
5,725
High price all time
1,421
Piotroski score
₹2.0
Graham Number
785.0
No. Eq. Shares
83.5
Net CF
₹749
Net profit
5,743
Price to book value
3.09
Interest Coverage
₹26.2
Low price all time
60.5
Industry PE
33.5
Reserves
₹33,466
Free Cash Flow
₹1,327

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
DR.REDDYS LABORATORIES LTD.88624.014099.085721.017.021,03,74418.3
Mankind Pharma Limited26055.84127.625413.69.9910296254.5
Zydus Lifesciences Limited27454.03847.025883.03.829955721.4

Peer Comparison Chart


About DRREDDYS LABORATORIES

Dr. Reddy's Laboratories Ltd.,, with Security Code 500124, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

(19 Aug 2025)
Baar, Switzerland; Aug 19 (Bernama) --. Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's...
Read more →

Extrovis AG and Dr. Reddy’s announce the launch of the

(18 Aug 2025)
Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S....
Read more →

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Bought by National Bank of Canada FI

(18 Aug 2025)
National Bank of Canada FI grew its position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 331.2% during the first quarter,...
Read more →

Dr Reddy's Secures CDSCO Panel Approval to Import, Market Olutasidenib for AML

(17 Aug 2025)
New Delhi: In a significant development, the pharmaceutical major, Dr. Reddy's Laboratories, has got the go-ahead from the Subject Expert...
Read more →

DRREDDY Outlook for the Week (August 18, 2025 – August 22, 2025)

(15 Aug 2025)
Technically, Dr Reddys Laboratories share price will see immediate support at 1,221.00 and immediate resistance would be seen at 1,282.90.
Read more →

AIA Group Ltd Sells 101,293 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)

(14 Aug 2025)
AIA Group Ltd decreased its position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 69.8% during the first quarter,...
Read more →

Company Updates